Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant Myocet plus paclitaxel, trastuzumab, and pertuzumab in operable HER2-positive breast cancer
2012-001201-24Phase 2Completed
- Sponsor
- SOLTI
- Start
- Oct 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, paclitaxel, trastuzumab and pertuzumab in breast cancer, sponsored by SOLTI. Primary endpoint: Rate of symptomatic and asymptomatic cardiac events during study treatment. Started Oct 2012; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-001201-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001201-24.